MedTrace Logo

Efficacy of Unani Formulations (HBR and SBM) for Treating Uncomplicated UTIs

NCT06742918 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-12-19

No results posted yet for this study

Summary

Based on a huge literature search a gap is found for a complete cure of Urinary Tract Infection (UTI) through the management of traditional antibiotic medicine. Therefore, there is a need to develop a cost-effective, easily available, and more potent drug for the management of UTI.

The objective of the study is as follows.

1. UTI in women is a neglected area in underdeveloped countries due to behavioral factors and zero death ratio in women therefore conduct a clinical study of the Unani formulation to assess the efficacy of the formulation.
2. The prices of allopathic medicines are increasing day by day so the investigator wants to give a cost-effective alternative solution.
3. To explore alternative treatments for Urinary Tract Infections with no or less antimicrobial resistance.

It is a comparative study comparing two formulations in three groups. Participants of Group-I received tablet HBR (HBR group), group-II was given syrup SBM (SBM group) and group-III was given a combination of tablets and syrup (HBR+SBM group) daily twice on an empty stomach for 14 days.

Participants visited the clinic after taking medicine for one week and then the second week.

On the first visit and day 14, patients had their checkups and tests. Hence, the justification for this study is to identify the antimicrobial activity of locally available plant materials and their formulations i.e. HBR and SBM, which have been used in Unani medicine practice for a long. Moreover, conduct a clinical trial for the determination of efficacy and drug resistance of these formulations.

Conditions

Interventions

OTHER

Placebo

Placebo was given to the Group IV which was 2 grams of glucose.

Sponsors & Collaborators

  • Hamdard University

    lead OTHER

Principal Investigators

  • Tabiba Huma Sayeed Siddiqui, M.Phil · Hamdard University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2021-09-11
Completion
2021-12-14

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06742918 on ClinicalTrials.gov